US-based Virtual Incision has secured an $18m Series B funding for the development of miniaturised surgical robots.

Led by Sinopharm Capital and Bluestem Capital, the funding round involved additional investors such as PrairieGold Venture Partners.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Virtual Incision intends to use the funds to support the 510(k) premarket notification submission for its next-generation miniaturised robotically assisted surgical device (RASD) to the US Food and Drug Administration (FDA).

Virtual Incision president and CEO John Murphy said: “Closing this round of financing launches the development of our miniaturised surgical robot toward our next key milestones, including submission to the FDA for market clearance.”

The firm is developing the RASD to allow less-invasion during general surgery abdominal procedures that are currently performed using large, open incisions.

"Our robot is designed to be moved from suite to suite as needed, providing the surgical staff with much more flexibility when it comes to the tools being used."

RASD is designed as a small, dexterous and self-contained surgical robot that enables insertion through an umbilical incision in the abdomen.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The technology is said to leverage existing tools and techniques and does not require a special operating room or infrastructure.

Virtual Incision co-founder and chief technology officer Shane Farritor said: “The large footprint and dedicated operating suite required to house multi-port or single-port mainframe robots can limit access, especially in smaller hospitals that have only one robotic surgery system.

“In contrast, our robot is designed to be moved from suite to suite as needed, providing the surgical staff with much more flexibility when it comes to the tools being used during a procedure.”

The firm’s robotic platform employs artificial intelligence and machine learning technologies to track and guide instrument usage.